| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2462 | 2019 |
| Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study A Marabelle, DT Le, PA Ascierto, AM Di Giacomo, A De Jesus-Acosta, ... Journal of Clinical Oncology 38 (1), 1-10, 2020 | 2348 | 2020 |
| Tumour heterogeneity in the clinic PL Bedard, AR Hansen, MJ Ratain, LL Siu Nature 501 (7467), 355-364, 2013 | 1344 | 2013 |
| Tumour-and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review L Khoja, D Day, TWW Chen, LL Siu, AR Hansen Annals of Oncology 28 (10), 2377-2385, 2017 | 795 | 2017 |
| Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus–related oropharyngeal carcinomas SH Huang, W Xu, J Waldron, L Siu, X Shen, L Tong, J Ringash, A Bayley, ... Journal of clinical oncology 33 (8), 836-845, 2015 | 442 | 2015 |
| Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study C Hsu, SH Lee, S Ejadi, C Even, RB Cohen, C Le Tourneau, JM Mehnert, ... Journal of Clinical Oncology 35 (36), 4050-4056, 2017 | 427 | 2017 |
| Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE‐158 and KEYNOTE‐028 studies SA Piha‐Paul, DY Oh, M Ueno, D Malka, HC Chung, A Nagrial, RK Kelley, ... International journal of cancer 147 (8), 2190-2198, 2020 | 375 | 2020 |
| Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study AR Hansen, C Massard, PA Ott, NB Haas, JS Lopez, S Ejadi, ... Annals of oncology 29 (8), 1807-1813, 2018 | 342 | 2018 |
| Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab SV Bratman, SYC Yang, MAJ Iafolla, Z Liu, AR Hansen, PL Bedard, ... Nature Cancer 1 (9), 873-881, 2020 | 334 | 2020 |
| Pembrolizumab in patients with microsatellite instability–high advanced endometrial cancer: results from the KEYNOTE-158 study DM O'Malley, GM Bariani, PA Cassier, A Marabelle, AR Hansen, ... Journal of Clinical Oncology 40 (7), 752-761, 2022 | 290 | 2022 |
| Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group B Lacas, A Carmel, C Landais, SJ Wong, L Licitra, JS Tobias, B Burtness, ... Radiotherapy and Oncology 156, 281-293, 2021 | 252 | 2021 |
| Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ... Genome medicine 8, 1-12, 2016 | 249 | 2016 |
| Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic ranking M Poudineh, PM Aldridge, S Ahmed, BJ Green, L Kermanshah, V Nguyen, ... Nature nanotechnology 12 (3), 274-281, 2017 | 229 | 2017 |
| A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors TW Chen, AR Razak, PL Bedard, LL Siu, AR Hansen Annals of Oncology 26 (9), 1824-1829, 2015 | 220 | 2015 |
| Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): results from the IGCCCG update consortium S Gillessen, N Sauvé, L Collette, G Daugaard, R de Wit, C Albany, ... Journal of Clinical Oncology 39 (14), 1563-1574, 2021 | 155 | 2021 |
| Evaluation of clear cell, papillary, and chromophobe renal cell carcinoma metastasis sites and association with survival S Dudani, G De Velasco, JC Wells, CL Gan, F Donskov, C Porta, ... JAMA network open 4 (1), e2021869-e2021869, 2021 | 154 | 2021 |
| Hyperprogressive disease in early‐phase immunotherapy trials: clinical predictors and association with immune‐related toxicities Y Kanjanapan, D Day, L Wang, H Al‐Sawaihey, E Abbas, A Namini, ... Cancer 125 (8), 1341-1349, 2019 | 145 | 2019 |
| Immuno-oncology trial endpoints: capturing clinically meaningful activity V Anagnostou, M Yarchoan, AR Hansen, H Wang, F Verde, E Sharon, ... Clinical Cancer Research 23 (17), 4959-4969, 2017 | 142 | 2017 |
| Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumor R Leão, T van Agthoven, A Figueiredo, MAS Jewett, K Fadaak, J Sweet, ... The Journal of urology 200 (1), 126-135, 2018 | 138 | 2018 |
| Osteoradionecrosis of the mandible in patients with oropharyngeal carcinoma treated with intensity‐modulated radiotherapy F Caparrotti, SH Huang, L Lu, SV Bratman, J Ringash, A Bayley, J Cho, ... Cancer 123 (19), 3691-3700, 2017 | 138 | 2017 |
